Sandoz and Polpharma announce licensing deal for natalizumab biosimilar

Sep 3, 2019

Sandoz and Polpharma announced they have entered into a licensing deal for Polpharma’s natalizumab biosimilar.  Under the agreement, Polpharma will develop, manufacture and supply the product, while Sandoz will be responsible for commercialisation and distribution.

Print Page Mail Article